4TEEN4 Pharmaceuticals
4TEEN4 Pharmaceuticals develops innovative therapies and biomarkers for diagnosis, prediction, and treatment of Circulatory Shock.
4TEEN4 Pharmaceuticals develops innovative therapies and biomarkers for diagnosis, prediction, and treatment of Circulatory Shock.
4TEEN4 Pharmaceuticals has raised $35.9M across 1 round. Its most recent round was a Series C of $35.9M in Nov 2025. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
4TEEN4 Pharmaceuticals is featured in
Similar companies
Dayra Therapeutics manufactures peptide based medicines.
Kind Pharmaceutical is a clinical-stage biopharmaceutical company that focuses on the discovery and development of anemia drugs.
Surv Biopharma develops a drug discovery platform that facilitates research and development of veterinary drugs and pharmaceutical products.
Brise Pharma operates in the scientific research and technical service industry.
Vybio is a high-tech enterprise focusing on innovative drug research and development.
Chirality Biosciences is a developer of chiral molecule separation technology enabling faster, safer, and side-effect-free drug production.
Bexorg provides a technology platform for central nervous system drug discovery and development.
Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC).
AeroRx Therapeutics is a biopharmaceutical company that developing proprietary, combination products.
OncoC4 is a biopharmaceutical company that engages in the discovery and development of novel biologicals for cancer treatment.
AusperBio is a biotechnology company that develops innovative drugs for curing chronic hepatitis B and other major infectious diseases.
Oligon is an emerging biotechnology company developing a novel class of multimodal RNA therapeutics.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.